关键信息
-
基因名
VTCN1
- 应用
-
别名
VTCN1；B7H4；V-set domain-containing T-cell activation inhibitor 1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q7Z7D3
-
表达区间
29-258aa
-
氨基酸序列
FGISGRHSITVTTVASAGNIGEDGILSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTAVFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAFSMPEVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQGANFSEVSNTSFELNSENVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTESEIKRRSHLQLLNSKA
-
分子量
27.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
VTCN1, also known as V-set domain containing T cell activation inhibitor 1, is a critical immune regulatory protein involved in the modulation of T cell responses. Its primary role is to inhibit T cell activation and promote immune tolerance, making it an important focus in cancer immunotherapy and autoimmune disease research. The dysregulation of VTCN1 has been associated with various malignancies, where tumor cells exploit this pathway to evade immune surveillance. Studies have shown that VTCN1 interacts with immune checkpoints, leading to the suppression of T cell activities. As a result, the recombinant production of VTCN1 protein has gained attention for its potential therapeutic applications. Researchers aim to create VTCN1-based agents that can either block its inhibitory effects to unleash anti-tumor immunity or enhance its function in cases of autoimmune disorders. Understanding the structural and functional properties of VTCN1 is essential for designing effective therapies, and ongoing investigations focus on its role in immune interaction networks. Overall, VTCN1’s significance in the immune landscape highlights the need for extensive research into its pathways and functions in various disease contexts.
